Levovar (Carbidopa, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter deficient in Parkinson's disease. Carbidopa inhibits the peripheral enzyme that would otherwise convert levodopa outside the brain, allowing more levodopa to reach the central nervous system and reducing peripheral side effects.

The appropriate dose of Levovar is individualized by the prescribing clinician based on disease severity, patient response, age, and tolerability. Physicians typically start with a low dose and adjust gradually to achieve optimal symptom control while monitoring for side effects.

Safety data for carbidopa/levodopa in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To request Levovar, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Levovar combines a dopamine precursor (levodopa) with a peripheral decarboxylase inhibitor (carbidopa), offering more efficient brain delivery than levodopa alone. Compared with dopamine agonists, it provides stronger symptomatic relief but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors and treatment goals.

Levovar tablets should be stored at room temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Levovar is taken orally, usually with a glass of water. It may be administered with or without food, but high‑protein meals can interfere with absorption, so clinicians often advise spacing the dose from protein‑rich meals to optimise effectiveness.

Serious risks include the development of psychosis or hallucinations, severe hypotension leading to fainting, and dyskinesia—uncontrolled involuntary movements. Patients should report any new psychiatric symptoms, marked drops in blood pressure, or abnormal movements to their healthcare provider promptly.

Levovar is contraindicated in patients with known hypersensitivity to carbidopa, levodopa, or any excipients. It should also be avoided in individuals taking non‑selective MAO inhibitors, and caution is advised for those with severe cardiovascular disease, narrow‑angle glaucoma, or a history of malignant neuroleptic syndrome.